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Abstract
Background: The incidence of nonalcoholic fatty liver disease (NAFLD) has been increasing worldwide in parallel
with the obesity epidemic. This study aims to investigate the effects of the total flavonoids in Stellera chamaejasme
L. (TFSC) on the experimental NAFLD in high fat diet fed (HFD) rats.
Methods: NAFLD model was induced in male Wistar rats by high-fat diet, and the rats in NAFLD group were
randomized into NAFLD group (n = 20) and TFSC-treated group (n = 60). Both groups were given high-fat diet, and
the normal group (n = 20) was given normal diet. In addition, the TFSC treated group was administered TFSC orally
once a day at a low dose of 100 mg/kg (n = 20), medium dose of 200 mg/kg (n = 20), and high dose of 400 mg/kg
(n = 20) for 6 weeks. Subsequently, the rats were sacrificed and body weight changes, lipid profiles in plasma and
liver pathology were examined. The relative levels of fatty acid synthesis and β-oxidation gene expression in
hepatic tissues were measured by quantitative real-time polymerase chain reaction (RT-PCR).
Results: After the HFD administration for 4 weeks, the body weight,serum TC and TG levels in the rat of model
group were significantly higher than in normal group (P < 0.05), and which Showed that the experimental NAFLD
model was successfully established. While continual feeding with HFD deteriorated NAFLD and hyperlipidemia, and
treatment with the different doses of TFSC effectively improved serum and liver lipid metabolism and liver function.
A linear relationship between the dose of TFSC and blood lipid level was observed. The mRNA expression of
hepatic acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), Leptin (LEP) and sterol regulatory element binding
protein (SREBP)-1c as well as peroxisome proliferator-activated receptor (PPAR) –γ were significantly lower in
high-dose group compared to the positive control group (P < 0.05). The hepatic mRNA expression of Cholesterol
7α-hydroxylase1 (CYP7A1), Carnitine palmitoyltransferase-1 (CPT1) and peroxisome proliferator-activated receptor
(PPAR) –α were significantly higher in the high-dose group compared to the positive control group (P < 0.05).
However, no difference was detected in the middle-dose group or the low-dose group compared to the positive
control group (P > 0.05).
Conclusion: TFSC treatment effectively improved NAFLD-related hyperlipidemia and inhibited liver steatosis in rats,
and accompanied by modulating the expression of genes for regulating lipid metabolism.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is a common
hepatic disease. Pathologically, it can present as simple
steatosis, non-alcoholic steatohepatitis (NASH), and
eventually progress to cirrhosis, an end-stage liver dis-
ease [1, 2]. The NAFLD is the most common cause of
chronic liver disease in western world, and it has been
increasing in China in the past years. The prevalence of
NAFLD ranges from 6 % to 14 % in different popula-
tions [3, 4]. The median prevalence of ultrasonographic
steatosis in Chinese populations is about 10 %, with a wide
range of 1 % to more than 30 % [5]. Notably, 1 %–5 % of
patients with simple steatosis can eventually develop
actual cirrhosis, and 10 % to 15 % of patients with
NASH can progress to cirrhosis and even to hepatocel-
lular carcinoma [2].
In recent years, many synthetic drugs have been used
to treat NAFLD problems. With various mechanisms of
action, these drugs have different side effects, some of
which could lead to severe complications. There has
been an active effort of screening traditional Chinese
medicine (TCM) to treat this fatal diseases [6].Our
study aims to investigate the potential of Stellera cha-
maejasme L., a type of TCM, in preventing and treating
NAFLD.
Stellera chamaejasme L. is a plant in the family Thy-
melaeaceae. It grows widely in mountain slopes, grass-
land, and valleys in northern and western China [7].
Stellera chamaejasme L., particularly the root, is toxic.
Eating Stellera chamaejasme L. causes diarrhea, vomit-
ing, and possible death in the livestock of these areas
[8]. However, the roots of Stellera chamaejasme L.,
called Langdu in traditional Chinese medicine, have
long been used to expel water retention, clear phlegm,
relieve masses, and destroy parasites [9]. Studies to
identify and isolate individual compounds from Stellera
chamaejasme L. have shown that the main chemical
components of Stellera chamaejasme L. include flavo-
noids, coumarins, diterpenes, triterpenes, lignins, and
phenylpropanoid glucosides [10, 11]. A recent study
showed a low acute toxicity of total flavonoids ex-
tracted from Stellera chamaejasme L. with the median
lethal dose (LD50) of 1.9848 g/kg in Balb/C mice, sug-
gesting the total flavonoid extract is a promising natural
medicine in drug development [12].
To the best of our knowledge, no studies has investi-
gated the effects of dietary supplementation with Stel-
lera chamaejasme L. stem extracts on fat metabolism
in a high-fat diet (HFD)-induced NAFLD model. In
this study, we examined the effects of TFSC on lipid
levels and cholesterol levels in the liver and serum of
rats fed with HFD, and on expression of genes in-




Total flavonoids were extracted from Stellera chamae-
jasme L. using ultrasonic extraction following the proce-
dures detailed by Wu et al. [13]. Briefly, 300 g Stellera
chamaejasme L. powder was soaked in 95 % EtOH, and
then was extracted 3 times using ultrasound for 30 min
each time at 50 °C with the solid–liquid ratio of 1:30.
The suspension was concentrated under reduced pres-
sure and then extracted with 50 mL petroleum ether
(PE) 3 times. The PE extract was concentrated under re-
duced pressure to yield a dark concrete. Fifty mL dis-
tilled water was added to the concentrate, which was
then heated in a water bath at 60 °C for 2 h, allowed to
stand until it reached room temperature, and then fil-
tered. The residue was taken and the processes of adding
distilled water, heating in a water bath, and filtering were
repeated 3 times.The residue was then evaporated.
Measurement of total flavonoids
The total flavonoid content was determined as previ-
ously described [13] with slight modifications. Briefly,
0.25 mL of SBS extracts (100 μg/mL) was added to a
tube containing 1 mL of double-distilled water. Next,
0.075 mL of 5 % NaNO2, 0.075 mL of 10 % AlCl3, and
0.5 mL of 1 M NaOH were added sequentially at 0, 5,
and 6 min. Finally, the volume of the reacting solution
was adjusted to 2.5 mLwith double-distilled water. The
solution had an absorbance of 510 nm, which was de-
tected using an Ultrospec TU-1901 Pro Spectrophotom-
eter (Purkinje General, china). The final concentrate was
the total flavonoid extract of 27.5 % content.
Animals
Normal Male Wistar rats weighing 160–180 g were pur-
chased from Inner Mongolia University Experimental
Animal Center. Ten rats were placed in one cage
and maintained under controlled room temperature
(20 ± 2 °C) and relative humidity (50–70 %) with day/
night cycle (12 h/12 h). All rats had free access to food
and water. The animal care and study protocols were
maintained in accordance with the Provisions and General
Recommendation of Chinese Experimental Animals
Administration Legislation [3].
Treatment of animals
Rats were fed with normal pellet diet (NPD) and water
ad libitum for 7 days to stabilize their metabolic condi-
tion. After the 1-week adaptation, the rats were ran-
domly divided into NPD group (n =40) and NAFLD
group (n = 100) randomly. NPD group was given normal
pellet diet and NAFLD group was given high fat diet, in
which 10 % lard (w/w), 10 % yolk powder, 2 % choles-
teroland, 0.2 % cholate were added into normal diet [14].
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After 4 weeks, all rats were fasted overnight for 12 h,
and retro orbital bleeding was conducted for analysis of
TG, TC, LDL-C, HDL-C, ALT, and AST in plasma. Be-
sides, five rats in each group were sacrificed randomly.
The livers were collected, and pathological changes in
the liver tissues were examined by H&E staining.
With successfully making the NAFLD model, the rats
in NAFLD group were randomized into four groups of
20 rats each. This four groups were given high-fat diet
and normal group (negative control, n = 20) was given
normal diet as before. they were given rat mash and
water ad libitum, and subjected to different dosages of
the TFSC viz: group A (positive control) received an
equivalent volume of water, group B, 100 mg/Kg body
weight of TFSC, group C, 200 mg/Kg body weight of
TFSC, group D.400 mg/Kg body weight of TFSC and
group E (negative control) received water and normal
standard feeds for 6 weeks.
Blood and tissue sample processing
After the experimental period, the rats were sacrificed
following 16 h of starvation, by decapitation. The liver
were removed quickly, weighed, and stored at −70 °C
until it was analyzed. Blood samples were collected and
centrifuged at 3,000 rpm at 4 °C for 15 min, and the
supernatants were stored at −70 °C for biochemical
analysis.
Biochemical analysis
The levels of triglyceride (TG), total cholesterol (TC), low-
density lipoprotein cholesterol (LDL-C), high-density lipo-
protein cholesterol (HDL-C), alanine transaminase (ALT),
aspartate aminotransferase (AST), total bile acid (TBA)
and blood glucose (GLU) in the serum were measured by
the enzymatic colorimetric method using commercial
Reagents assay kits (Beijing Biosino Bio-technology &
Science Inc, China); The serum concentration of glutathi-
one peroxidase (GSH-Px), Total superoxide dismutase
(T-SOD), malondialdehyde (MDA), lactate dehydrogenase
(LDH) and Leptin were analyzed using a commercial assay
kit (Nanjing Jiancheng Bioengineering Institute, China)
according to the manufacturer’s instructions.
Hepatic lipids analyses
Hepatic lipids were extracted using the method of Bligh
and Dyer [15], with slight modifications. Briefly, hepatic
tissues (500 mg) were homogenized in 1.5 mL of 0.9 %
saline, and 7.5 mL of methanol: chloroform (2:1, v:v)
was added to the homogenates. The mixture was shaken
horizontally for 10 min and centrifuged at 2,000 × g for
10 min. The lower chloroform phase was withdrawn,
and the lipid in this phase was dried and weighed. TC
and TG concentrations were determined by enzymatic
colorimetric methods using commercial kits as described
above.
Histological analysis of the liver
After six weeks of intervention, the rats were sacrificed
and their livers were fixed by 10 % buffered formalin
and embedded in paraffin. The liver sections (5 μm)
were stained with hematoxylin and eosin (H&E), and the
steatoic degrees of individual liver samples were exam-
ined and scored, according to the percentage of hepato-
cytes containing lipid droplets [2, 16] by a pathologist in
a blinded manner.
Extraction and analysis of RNA and analysis of gene
expressions
Total RNA was extracted from liver tissue samples using
TRIZOL (Invitrogen, USA) according to the manufac-
turer’s protocol. RNA from Liver samples were extracted
for analyzing ACC, CPT-1, PPAR-α, PPAR-γ, SREBP-1c,
FAS, LEP and CYP7A1 gene expression, 3.0 μg of the
total RNA was reverse-transcribed by Revert Aid First
Strand cDNA synthesis kit (TaKaRa Bio Inc.). Real-time
quantitative PCR was performed using the SYBRPremix
Ex TaqTM (TaKaRa Bio Inc.) according to the manufac-
turer’s instructions on ABI 7900HT real-time PCRsys-
tem (Applied Biosystems, Foster, CA, USA) with primers
as shown in Table 1. The ΔΔCt method was used for
relative quantification. The ΔΔCt value for each sample
was determined by calculating the difference between
the Ct value of the target gene and the Ct value of the β-
actin reference gene. The normalized level of expression




All values were expressed as mean ± SD and were ana-
lyzed using the statistical package for thesocial science
(SPSS, version 20). Duncan multiple values test and stu-
dents t–test were used to detect differences in the mean
values of treatment groups and control at significance
level of 0.05.
Results
The feeding of high-fat diet for 4 weeks effectively
induced NAFLD in rats, as evidenced by the markedly
increased body weight, liver weight, and serum TG, TC,
LDL-C, ALT, AST and TBA, while decreasing HDL-C
(Table 2). Furthermore, H&E staining results (Fig. 1(b))
showed that steatosis was developed and numerous lipid
droplets were observed in all of the five livers from the
NAFLD rats. This high-fat-diet-induced NAFLD model
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has the same key pathological features as those reported
for other rat NAFLD models [3, 17, 18]. Based on the
previous results, the NAFLD model was considered to
be successfully established.
In the following 6 weeks, rats of high-dose group and
middle-dose group showed significantly reduced body
weight (by 5.89 % and 4.10 % respectively (P < 0.05 for
both), liver weight (by 24.99 %, P < 0.01 and 17.87 %, P <
0.05 respectively), and liver index (liver/body weight, by
21.02 %, P < 0.01 and 15.10 %, P < 0.05 respectively)
compared with rats with the positive control group
(NAFLD rats). No statistical difference was found between
Low-dose group and the positive control group (Table 2).
Results of AST, ALT, TG, TC, LDL-C, HDL-C,
GLU,TBA, Leptin, concentration of rats administered
different doses of TFSC are shown in Tables 3. Rats ad-
ministered 400 mg/kg body weight of TFSC had signifi-
cant (P < 0.01) decrease in TG, TC and MDA compared
with the positive control group, while the groups admin-
istered 200 mg/kg and 100 mg/kg did not differ signifi-
cantly in TG and TC, but had decreased and MDA
compared with the positive control group (P > 0.05). Rats
administered 400 mg/kg body weight of TFSC had sig-
nificant (P < 0.05) decrease in AST, ALT, LDL-C and
TBA compared with the positive control group, while
the groups administered 200 mg/kg and 100 mg/kg did
not differ significantly in AST, ALT, LDL-C, but had de-
creased TBA compared with the positive control group
(P > 0.05). Rats administered 400 mg/kg body weight of
TFSC had significant (P < 0.05) increase in HDL-C com-
pared with the positive control group, while the groups
administered 200 mg/kg and 100 mg/kg did not differ
significantly in HDL-C compared with the positive con-
trol group (P > 0.05). Meanwhile, hepatic histopatho-
logical examination showed the steatosis area and the
number of lipid droplets were decreased in the different
Table 1 Primers used for quantitative real-time polymerase chain reaction (PCR)
Gene Primer pairs Sequence( 5′→ 3′) GenBank no Product length(bp)
CYP7A1 Sense primer AAAGCGGGAAAGCAAAGACCA NM_012942 157
Antisense primer AGTTCAAAGCAGGAGAGCATCAGG
CPT-1 Sense primer CCGCAAACTGGACCGAGAAGAGAT AF029875 185
Antisense primer TTTGCCTGGGATGCGTGTAGTGTT
PPAR-α Sense primer TACCTGTGAACACGATCTGA NM_013196 136
Antisense primer GCTAGTCTTTCCTGCGAGTA
PPAR-γ Sense primer TGTGGGGATAAAGCATCAGC NM_001145366 175
Antisense primer CAAGGCACTTCTGAAACCGA
SREBP-1c Sense primer AGGAGGCCATCTTGTTGCTT AF286470 126
Antisense primer GTTTTGACCCTTAGGGCAGC
ACC Sense primer GGAAGACCTGGTCAAGAAGAAAAT NM_022193 142
Antisense primer CACCAGATCCTTATTATTGT
β-actin Sense primer GGCACCACACTTTCTACAAT NM_031144 123
Antisense primer AGGTCTCAAACATGATCTGG
Leptin Sense primer TGCCTATCCACAAAGTCCAG NM_013076.2 381
Antisense primer TGCTCAGAGCCACCACCT
FAS Sense primer CGGCGTGTGATGGGGCTGGTA NM_017332 145
Antisense primer AGGAGTAGTAGGCGGTGGTGTAGA
















Body weight (g) 324.86 ± 24.17 341.45 ± 17.2★ 365.35 ± 15.23 393.33 ± 23.17* 380.61 ± 23.87*# 373.52 ± 18.88# 396.89 ± 21.22
Liver weight (g) 10.29 ± 0.98 14.39 ± 1.06★★ 11.65 ± 0.98 18.53 ± 1.26** 16.04 ± 1.17**# 14.65 ± 1.08*## 19.53 ± 1.25
Liver/body weight (%) 3.17 ± 0.17 4.21 ± 0.23★★ 3.19 ± 0.23 4.71 ± 0.12** 4.16 ± 0.22*# 3.87 ± 0.19*## 4.92 ± 0.35
★P < 0.05, ★★P < 0.01, compared to normal control group (4w). *P < 0.05, **P < 0.01, compared to normal group (6w); #P < 0.05, ##P < 0.01, compared to positive
control group (6w)
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doses of TFSC-treated group, indicating the improve-
ment of liver steatosis (Fig. 1d, e, f ).
The results showed that TFSC significantly increased
in T-SOD, GSH-Px activity and reduced in MDA level
both in rat serum.
After stained with H&E, the degrees of hepatic steato-
sis were examined. While there was no obvious steatosis
in the liver of the normal group of rats, different degrees
of liver steatosis were observed in other group rats
(Figs. 1 and 2). The area of hepatic steatosis in the high-
dose group decreased remarkably when compared with
that in the positive control group (P < 0.01), in the
middle-dose group decreased when compared with that
in the positive control group (P < 0.05), the score of
hepatic steatosis in the low-dose group decreased when
compared with that in the positive control group
Fig. 1 H&E staining for histological evaluation. Typical photographs of liver sections of normal rat (a) and NAFLD rat (b) in 4 weeks; (c)normal rat
(negative control group); (d) the rat treated with TFSC (100 mg/kg) for 6 weeks; (e) the rat treated with TFSC (200 mg/kg) for 6 weeks; (f) the rat
treated with TFSC (400 mg/kg) for 6 weeks; (g) positive control group. (Magnification 400x)
Table 3 Effect of total flavonoids in Stellera chamaejasme L. on serum lipid level in rats (mean ± SD) (n = 20)
Parameter 4w 6w
Normal group NAFLD group Normal group Low-dose group Middle-dose group High-dose group Positive control group
AST (U/L) 75.17 ± 4.31 96.85 ± 7.63★★ 76.29 ± 5.16 97.36 ± 6.82** 93.75 ± 4.55* 88.34 ± 6.27*# 101.67 ± 8.36
ALT(U/L) 28.16 ± 1.21 51.28 ± 3.26★★ 29.25 ± 1.72 53.28 ± 4.41** 49.78 ± 2.19** 44.29 ± 2.22**# 56.35 ± 4.16
TG(mmol/L) 0.59 ± 0.09 1.65 ± 0.08★★ 0.61 ± 0.04 1.81 ± 0.11** 1.46 ± 0.09**# 0.92 ± 0.03**## 2.12 ± 0.12
TC(mmol/L) 1.66 ± 0.12 3.14 ± 0.13★★ 1.70 ± 0.09 3.82 ± 0.15** 3.65 ± 0.17**# 2.65 ± 0.12**## 4.54 ± 0.24
LDL-C (mmol/L) 0.54 ± 0.03 1.25 ± 0.08★★ 0.56 ± 0.04 1.37 ± 0.08** 1.24 ± 0.05** 1.09 ± 0.06**# 1.35 ± 0.09
HDL-C (mmol/L) 0.96 ± 0.04 0.64 ± 0.04★★ 0.98 ± 0.05 0.64 ± 0.03** 0.69 ± 0.05** 0.77 ± 0.04*# 0.55 ± 0.03
GLU (mmol/L) 4.68 ± 0.15 5.07 ± 0.21 4.56 ± 0.18 4.99 ± 0.87 5.07 ± 0.04 5.13 ± 18.88 5.41 ± 0.19
TBA(μmol/L) 6.75 ± 0.05 10.23 ± 0.06★★ 6.54 ± 0.06 11.53 ± 1.27** 11.04 ± 0.98** 10.24 ± 0.05**# 12.27 ± 1.25
Leptin (μg/L) 0.18 ± 0.01 0.32 ± 0.01★ 0.19 ± 0.02 0.46 ± 0.03** 0.34 ± 0.02*# 0.28 ± 0.01# 0.46 ± 0.03
SOD (U/mL) 374.36 ± 17.86 300.4 ± 20.1★★ 370.35 ± 19.46 293.4 ± 24.1** 321.79 ± 23.16* 348.32 ± 19.76# 297.84 ± 23.17
MDA (nmol/mL) 3.26 ± 0.21 4.27 ± 0.16★★ 3.25 ± 0.75 4.98 ± 1.32* 4.77 ± 0.87* 3.84 ± 0.99## 5.04 ± 1.27
GSH-Px (U/mL) 256.21 ± 19.25 210.45 ± 14.2★ 255.98 ± 20.54 206.88 ± 15.3** 211.57 ± 17.45**# 238.78 ± 14.25# 194.21 ± 17.35
★P < 0.05, ★★P < 0.01, compared to normal control group (4w). *P < 0.05, **P < 0.01, compared to normal group (6w); #P < 0.05, ##P < 0.01, compared to positive
control group (6w). Normal Group: the group was given normal diet (n = 20) for 4 weeks; NAFLD Group: the group was given high-fat diet (n = 20) for 4 weeks;
Negative Control Group: After the normal diet of 4 weeks, the group was given normal diet (n = 20) for 6 weeks; Low-dose group: After the HFD of 4 weeks, the
group was administered TFSC orally once a day at a low dose of 100 mg/kg (n = 20) for 6 weeks; Middle-dose group: After the HFD of 4 weeks, the group was
administered TFSC orally once a day at a medium dose of 200 mg/kg (n = 20) for 6 weeks; High-dose group: After the HFD of 4 weeks, the group was administered
TFSC orally once a day at a high dose of 400 mg/kg (n = 20) for 6 weeks; Positive control group: After the HFD of 4 weeks, the group was given high-fat diet
(n = 20) for 6 weeks
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(P > 0.05), however, they remained significantly higher
than that of the high-dose group or middle-dose group.
There was no significant difference in the score of liver
steatosis between the high-dose group and middle-dose
group (P > 0.05) (Figs. 1 and 2).
We next examined whether the different doses of
TFSC supplementation affected mRNA expression of
genes involved in hepatic lipid metabolism in liver sam-
ples of rats. The mRNA levels of genes such as PPAR-γ,
SREBP-1c, ACC, FAS and LEP showed a 53 %, 35 %,
47 %, 48 % and 43 % decrease, respectively, in the high-
dose group compared with those of the positive control
group (NAFLD rats) (Fig. 3a). the mRNA levels of
PPAR-γ, SREBP-1c, ACC, FAS and LEP showed a 15 %,
26 %, 19 %, 19 % and 22 % decrease, respectively, in
middle-dose group, compared with those of the positive
control group (NAFLD rats) (Fig. 3a). Also, the mRNA
levels of PPAR-γ, SREBP-1c, ACC, FAS and LEP showed
a 6 %, 7 %, 14 %, 16 % and 13 % decrease, respectively,
in the low-dose group, compared with those of the posi-
tive control group (NAFLD rats) (Fig. 3a). The mRNA
levels of PPAR-α, CPT-1, and CYP7A1 showed 3.26-,
3.35-, and 2.56-fold increase, respectively, in the high-
dose group compared to the positive control group
(Fig. 3b). The mRNA levels of PPAR-α, CPT-1, and
CYP7A1 showed 2.01-, 1.58-, and 1.85-fold increase, re-
spectively, in the middle -dose group compared to the
positive control group (Fig. 3b). The mRNA levels of
PPAR-α, CPT-1, and CYP7A1 showed 1.27-, 1.21-, and
1.38-fold increase, respectively, in the low-dose group
compared to the positive control group (Fig. 3b).
Our studies indicated that TFSC had lowering lipid
and hepatoprotective effect, and regulated and improved
the balancing effects of free radicals on rat model of
NAFLD. It’s possible mechanism is that TFSC downreg-
ulating the mRNA expression of transcription factor
SREBP-lc to regulate the downstream lipid synthesis re-
lated genes ACC, FAS and LEP expression, meanwhile,
TFSC upregulated the level of transcription factor
PPAR-α to regulate the downstream lipidolysis related
genes CPT-1 and CYP7A1 expression, and improved the
liver tissue β oxidation and in vivo fatty acid degrad-
ation, inhibit fatty acid synthesis, and finally reach the
effective regulation of lipid metabolisms of experimental
rat model of NAFLD (Table 4).
Discussion
NAFLD is a common chronic liver disease worldwide
and its incidence is increasing in developed countries
[3]. Over-consumption of high calories of foods, particu-
larly HFD, is crucial for the development of NAFLD.
The treatments of NAFLD currently include oral drug
therapy, TCM therapy and exercise therapy. All of these
existing traditional drug treatments seem to be ineffi-
ciant, therefore it is necessary to find drugs with better
effect and fewer side-effects. Recently, many studies have
shown that some active ingredients in crude chemicals
have stable efficacy in prevention and treatment of
NAFLD, and with less toxicity and fewer adverse reac-
tions, which can be made long-term use of (references).
Among these, the total flavonoids in Stellera chamae-
jasme L. (TFSC) and its derivatives with its unique phys-
ical and properties has been research hotspot of the
world since 1980s, and has made big progress in medi-
cine, food and chemical industry, environmental protec-
tion, agriculture and many other fields [19, 20]. Recent
studies have shown that treatment with flavonoids also
benefits patients with NASH and NAFLD [21], However,
Fig. 2 Scores of hepatic steatosis of rat livers. The scores were determined, according to the the percentage of hepatocytes containing lipid
droplets. Data are expressed as mean ± SD of each group (n = 20 per group) and determined by a pathologist in a blinded fashion. *P < 0.05,
**P < 0.01, compared to normal control group, # P < 0.05, ## P < 0.01, compared to positive control group
Wang et al. Lipids in Health and Disease  (2015) 14:85 Page 6 of 9
the mechanisms responsible for lipid-lowering actions of
total flavonoids in Stellera chamaejasme L. (TFSC) on
liver remains unclear. In this study, we explored the
efficacy of the different doses of TFSC supplements
treatment on the HFD-induced hepatic steatosis and
hyperlipidemia in rats. We found that high-dose group
or middle-dose group treatment for 6 weeks significantly
inhibited the HFD-induced liver weights ,body weights
and reduced the ratios of liver to body weights in the
NAFLD rats. Furthermore, high-dose group or middle-
dose group treatment mitigated the HFD-induced hep-
atic steatosis, which was associated with the improve-
ment of liver and systemic lipid profiles and function,
leading to reduction in the severity of hyperlipidemia
in NAFLD rats. Whether TFSC treatment for a longer
period could prevent the development of NAFLD-
related liver fibrosis and how TFSC treatment could im-
prove lipid metabolism in advanced NAFLD, remain an
interest for future investigation.
Fig. 3 The expression of lipid metabolic regulators in the liver. (A) The expression of hepatic PPAR-γand related genes. The relative expression
levels of hepatic PPAR-γ, ACC, SREBP-1c, LEP and FAS mRNA transcripts were determinedby real-time PCR in liver samples of rats from the positive
control group (NAFLD rats) and the different doses of TFSC-treated group (n =20 per group). (B) The expression of CYP7A1and related genes. The
relative expression levels of hepatic CYP7A1, CPT-1 and PPAR-α mRNA transcripts were determined by real-time PCR in liver samples of rats
from the positive control group (NAFLD rats) and the different doses of TFSC-treated group (n =20 per group). Values are means ± positive
and negative errors. Differences between groups were determined by Student’s t test. *P<0.05; **P<0.01 versus the positive control group
(NAFLD rats). Abbreviations: CYP7A1, Cholesterol 7α-hydroxylase1; CPT, carnitine palmitoyltransferase; PPAR, peroxisome proliferator-activated receptor;
SREBP, sterol regulatory element-binding protein; ACC, Acetyl-CoA carboxylase, FAS, Fatty acid synthase, LEP, Leptin
Table 4 Effects of Total Flavonoids in Stellera chamaejasme L.
on liver lipid level in rats (mean ± SD) (n = 20)
Group Hepatic TC (mg/g) Hepatic TG (mg/g)
Normal group 0.89 ± 0.06 1.52 ± 0.11
Low-dose group 3.86 ± 0.26** 2.56 ± 0.16
Middle-dose group 3.16 ± 0.27**# 2.36 ± 0.12
High-dose group 2.19 ± 0.13** ## 1.78 ± 0.09##
Positive control group 4.37 ± 0.24 2.97 ± 0.19
*P < 0.05, **P < 0.01, compared to normal group (6w); #P < 0.05, ##P < 0.01,
compared to positive control group (6w)
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In this study, high-dose TFSC supplementation in rats
fed high fat diet was effective in decreasing liver trigly-
ceride and total cholesterol, and in increasing serum
SOD and GSH-Px. This study observed a decline in the
mRNA expressions of lipogenic enzymes such as ACC
and FAS in high fat with TFSC treatment group. A sig-
nificant decrease in the transcriptional factor of SREBP-
1c, PPAR-γ expression with TFSC supplement was also
found in this study. Therefore, lowered hepatic triglycer-
ide and cholesterol levels after TFSC supplementation in
high fat fed rats seem to be related with decreased tran-
scriptional factor, SREBP1-c and PPAR-γ which inhibits,
in turn, gene expressions of lipogenic enzymes such as
ACC and FAS, thus resulting in inhibiting accumulation
of triglycerides or cholesterol in liver. Lipid biosynthesis
usually occurs in hepatic tissue and typically involves the
following lipogenic enzymes: ACC and FAS [22]. In this
process, SREBP-1c and PPAR-γ function as an important
transcriptional factor that mediates and activates fatty
acid and cholesterol biosynthesis pathways [23, 24]. It is
believed that SREBP-1c and PPAR-γ greatly increase the
expression of genes related with lipogenic pathway in
liver [24, 25]. In this study, TFSC supplement led to in-
crease CPT1 expression in the TFSC supplement supple-
mented group than the high-fat diet group. Since CPT1
mediates the transport of acyl-CoA across the mem-
brane and stimulates the oxidation of long chain fatty
acids [25], it suggests that TFSC exhibited hepatic lipid
-lowering property which may be also partly mediated
via increase of hepatic CPT1 expression.
To understand how hepatic cholesterol content de-
creased by TFSC treatment, the genetic expression of
cholesterol metabolism regulating enzymes, such as
CYP7A1, were examined in this study. Human CYP7A1
gene defect can cause cholesterol accumulation in the
liver, which has been associated with hypercholesterol-
emia [26]. This study observed a significant increase in
CYP7A1 expression in the TFSC-treated group than the
high-fat diet group. This result indicates that TFSC-
treated consumption increases CYP7A1 expression in
liver and thus reducing cholesterol accumulation in
liver.
Conclusion
In this study, the HFD in the experiment can significantly
increase the body weight ,serum TC and TG levels, cause
severe lesions and fat mold in rat, showing that the experi-
mental fatty method was feasible and can meet the
demand of our research. The TFSC significantly reduced
the body weight and the serum biochemical indexes in
NAFLD rats, suggesting that it is the effective Chinese
medicine on NAFLD rat. The molecular mechanism may
be due to the down-ragulation of the level of PPAR-γ
mRNA, ACC mRNA, SREBP-1c mRNA, LEP mRNA, FAS
mRNA, and the up-ragulation of the level of CYP7A1
mRNA, CPT-1 mRNA and PPAR-α mRNA. The metabo-
lomic results not only provided a systematic view of the
development and progression of NAFLD, but also sug-
gested a theoretical basis for the prevention or treatment
of NAFLD.
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